Informations générales (source: ClinicalTrials.gov)
Use of Fc Mannose-Binding Lectin to Detect and Monitor the Presence of Pathogen-Associated Molecular Patterns During Septic Shock (Fc-MBL/PAMPs)
Interventional
N/A
University Hospital, Toulouse (Voir sur ClinicalTrials)
octobre 2018
juillet 2019
29 juin 2024
Use Mannose Binding Lectin (MBL) as a biomarker to measure levels of Pathogen- Associated
Molecular Patterns (PAMP) during septic shock. This will allow evaluating interest of
this biomarker to monitor and manage a septic shock. Consecutive patients admitted for
sepsis in Intensive Care Unit Department will be included. This biomarker will be
compared to all the parameters monitored usually for these patients in standard care.
Etablissements
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
University Hospital Toulouse - 31059 - Toulouse - France | Eric Oswald, MD | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- Adult patients
- Hospitalized in Intensive Care Unit for sepsis of any etiology
- Patients with shock criteria: defined by a hypotension, hyperlactatemia, the use of
vasopressive drugs.
- Patient affiliated to a social security scheme- Patient giving consent
- Adult patients
- Hospitalized in Intensive Care Unit for sepsis of any etiology
- Patients with shock criteria: defined by a hypotension, hyperlactatemia, the use of
vasopressive drugs.
- Patient affiliated to a social security scheme- Patient giving consent
- Minor patients
- Organ transplant
- Immunosuppressive drugs, other than corticosteroids
- Patients who decline participating to the assay
- Persons placed under legal protection, guardianship
- Pregnant woman
- Subject participating in another search including a exclusion period still in
progress at pre-inclusion